Systemic cellular immunity and neuroinflammation during acute flare-up in multiple sclerosis and neuromyelitis optica spectrum disorder patients

Nobuaki Uchida; Kentaro Mori; Michiyo Fujita-Nakata; Megumi Nakanishi; Mitsuru Sanada; Shigemi Nagayama; Hiroshi Sugiyama; Makoto Matsui

doi:10.1016/j.jneuroim.2021.577500

Systemic cellular immunity and neuroinflammation during acute flare-up in multiple sclerosis and neuromyelitis optica spectrum disorder patients

J Neuroimmunol. 2021 Apr 15:353:577500. doi: 10.1016/j.jneuroim.2021.577500. Epub 2021 Feb 10.

Authors

Nobuaki Uchida¹, Kentaro Mori¹, Michiyo Fujita-Nakata¹, Megumi Nakanishi¹, Mitsuru Sanada¹, Shigemi Nagayama¹, Hiroshi Sugiyama², Makoto Matsui³

Affiliations

¹ Department of Neurology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Kahoku-gun, Ishikawa 920-0293, Japan.
² Department of Neurology, National Hospital Organization Utano National Hospital, 8 Narutaki-Ondoyama-cho, Ukyo-ku, Kyoto 616-8255, Japan.
³ Department of Neurology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Kahoku-gun, Ishikawa 920-0293, Japan. Electronic address: [email protected].

PMID: 33592574
DOI: 10.1016/j.jneuroim.2021.577500

Abstract

Twenty-seven treatment-naïve patients with relapsing-remitting multiple sclerosis (MS) and 13 with neuromyelitis optica spectrum disorder (NMOSD) were enrolled during a time of acute flare-up. Common cerebrospinal fluid (CSF) features were increased CD29- and/or CD45RO-positive helper T cells capable of propagating inflammation in the central nervous system (CNS). B cell activation in the CSF was unique to MS, while an increase in CD4⁺CD192 (CCR2)⁺ cells in blood and breakdown of the blood-brain barrier (BBB) characterized NMOSD. Intravenous corticosteroid therapy suppressed neuroinflammation via modulation of cellular immunity in MS, as opposed to restoration of the BBB in NMOSD.

Keywords: Biomarker; Cerebrospinal fluid; Flow cytometry; Lymphocyte subset; Multiple sclerosis; Neuromyelitis optica spectrum disorder.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adrenal Cortex Hormones / therapeutic use
Adult
Aged
B-Lymphocytes / drug effects
B-Lymphocytes / immunology
Biomarkers / analysis*
Blood-Brain Barrier / drug effects
Blood-Brain Barrier / pathology
Female
Humans
Immunity, Cellular / drug effects
Immunity, Cellular / immunology*
Immunologic Factors / therapeutic use
Inflammation / blood
Inflammation / cerebrospinal fluid
Inflammation / immunology
Lymphocyte Activation / drug effects
Lymphocyte Activation / immunology
Lymphocyte Subsets / drug effects
Lymphocyte Subsets / immunology
Male
Middle Aged
Multiple Sclerosis, Relapsing-Remitting / blood
Multiple Sclerosis, Relapsing-Remitting / cerebrospinal fluid
Multiple Sclerosis, Relapsing-Remitting / immunology*
Neuromyelitis Optica / blood
Neuromyelitis Optica / cerebrospinal fluid
Neuromyelitis Optica / immunology*
Symptom Flare Up
T-Lymphocytes, Helper-Inducer / drug effects
T-Lymphocytes, Helper-Inducer / immunology

Substances

Adrenal Cortex Hormones
Biomarkers
Immunologic Factors